Abstract:

Objective To investigate the clinical significance of serum high mobility group protein B1 (HMGB1) and serum amyloid aprotein (SAA) levels in newborns with septic shock. Methods The serum HMGB and SAA levels of newborns were measured by enzyme-linked immunosorbent assay between shock group (n=87, cases with septic shock ) and normal group (n=50, cases with common infection), those cases were all born and treated in our hospital from August 2018 to August 2020. Results The serum HMGB1 and SAA levels of newborn in shock group were significantly higher than those in normal group (P<0.05); among neonatal septic shock children, the serum HMGB1 and SAA levels of surviving newborn were significantly lower than those of dead newborn (P<0.05). The serm HMGB1 level was significant positively correlation with the serum SAA level (r=0.708, P<0.05). Conclusion The higher the serum HMGB1 and SAA, the worse the prognosis of neonatal septic shock. The two items can be used as important indicators of the severity and prognosis of neonatal septic shock.

Key words: high mobility group proteins, amylases, infant, newborn, diseases